Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Achim Krüger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1517-9256; OpenAlex author ID A5074621493. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 13

  1. Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. Last author DOI 10.1016/j.xcrm.2025.102546↗
  2. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
  3. Extent of N-glycosylation of the metalloproteinase inhibitor and cytokine TIMP-1 determines pancreatic cancer cell proliferation and survival via CD63. Last author DOI 10.1016/j.jbc.2025.110211↗
  4. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  5. TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer. Last author DOI 10.1084/jem.20210911↗
  6. TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-20-4125↗
  7. Conformation-Specific Inhibitory Anti-MMP-7 Monoclonal Antibody Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Chemotherapeutic Cell Kill. Co-author DOI 10.3390/cancers13071679↗
  8. Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and… Last author DOI 10.1186/s12885-018-4055-9↗
  9. Corrigendum to "Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer" [J. Control. Release 239 (20… Co-author DOI 10.1016/j.jconrel.2017.07.027↗
  10. Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells. Co-author DOI 10.1073/pnas.1606909114↗
  11. Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2016.08.016↗
  12. Systemic Ablation of MMP-9 Triggers Invasive Growth and Metastasis of Pancreatic Cancer via Deregulation of IL6 Expression in the Bone Marrow. Last author DOI 10.1158/1541-7786.mcr-16-0180↗
  13. Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2014.10.020↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. İhsan Ekin Demir · 6 shared papers, 2017–2026 · strength 0.77
  2. Daniel Häußler · 4 shared papers, 2021–2026 · strength 0.67
  3. Carmen Mota Reyes · 4 shared papers, 2017–2026 · strength 0.54
  4. Olga Prokopchuk · 4 shared papers, 2018–2025 · strength 0.54
  5. Barbara T. Grünwald · 7 shared papers, 2015–2021 · strength 0.53
  6. Helmut Frieß · 3 shared papers, 2023–2025 · strength 0.51
  7. Kaan Çifcibaşı · 3 shared papers, 2023–2026 · strength 0.49
  8. Roland Rad · 3 shared papers, 2023–2026 · strength 0.49
  9. Dieter Saur · 3 shared papers, 2023–2026 · strength 0.49
  10. Julian Frädrich · 2 shared papers, 2025–2026 · strength 0.44
  11. Benjamin Schoeps · 3 shared papers, 2021–2025 · strength 0.39
  12. Hana Algül · 3 shared papers, 2017–2025 · strength 0.33
  13. Guralp Onur Ceyhan · 3 shared papers, 2017–2025 · strength 0.33
  14. Jan P. Böttcher · 2 shared papers, 2021–2026 · strength 0.33
  15. Stefanie Bärthel · 2 shared papers, 2023–2026 · strength 0.33
  16. Marc Eric Martignoni · 2 shared papers, 2018–2025 · strength 0.31
  17. Lei Ren · 2 shared papers, 2023–2025 · strength 0.28
  18. Linhan Ye · 2 shared papers, 2023–2025 · strength 0.28
  19. Alexander Muckenhuber · 2 shared papers, 2023–2025 · strength 0.28
  20. Kıvanç Görgülü · 2 shared papers, 2023–2025 · strength 0.28
  21. Saliha Elif Yıldızhan · 2 shared papers, 2023–2025 · strength 0.28
  22. Roland Michael Schmid · 2 shared papers, 2023–2025 · strength 0.28
  23. Chris D. Hermann · 2 shared papers, 2021 · strength 0.23
  24. Daniele Lucarelli · 1 shared paper, 2026 · strength 0.21
  25. Francisco X. Real · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.